MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%
Trevena, Inc.
TRVN Details
Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company specializing in the development and commercialization of innovative medicines for patients with central nervous system (CNS) disorders. TRVN presently only has one approved product, OLINVYK (oliceridine) injection, which is used to treat people who have severe acute pain that requires an intravenous opioid analgesic and for whom previous treatments have failed. TRV027 for acute lung damage, TRV250 for migraines, TRV734 for chronic pain and opioid use disorder, and TRV045 for epilepsy are among the company's other products in development.
Latest News:
Q3FY21 Results:
Risks:
Outlook:
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
TRVN Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
TRVN's share price has decreased 62.17% in the past six months and is currently leaning towards the lower end of its 52-week range of USD 0.56 to USD 3.10. The stock is currently trading below its 50 and 200 DMA levels, and its RSI Index is at 42.68. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 0.78.
Considering the correction in the stock price in the past six months, robust product pipeline, and associated risks, we recommend a "Speculative Buy" rating on the stock at the current price of USD 0.6355, up 9.10% as of January 03, 2022, 11:11 AM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
* Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached.